Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Breast Cancer
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-06
Study Details Design, interventions, and primary outcomes

About This Study

Breast cancer patients receiving chemotherapy often experience psychological distress, anxiety, and discomfort during treatment. Non-drug supportive methods may help improve patients' well-being during chemotherapy. This study aims to evaluate whether mandala coloring during outpatient chemotherapy can reduce psychological distress and anxiety and improve comfort in breast cancer patients. Participants will be randomly assigned to either a mandala coloring group or a routine care group. Patients in the intervention group will color mandala patterns for 30 minutes during their chemotherapy session, while the control group will receive routine care only. Psychological distress, anxiety, and comfort levels will be measured before and after the chemotherapy session in both groups. The results of this study may provide evidence for a simple and low-cost supportive intervention to improve the psychological well-being of breast cancer patients during chemotherapy.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Mandala Coloring — Mandala coloring activity performed for 30 minutes during outpatient chemotherapy using mandala coloring books and colored pencils.

Primary Outcomes

  • Psychological Distress (Before chemotherapy session and immediately after the chemotherapy session (single session).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-27
Completion: 2027-01-20
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Artvin Coruh University
Contact Information
Study Contact:
Efe Hasdemir Efe Hasdemir, MD
+90 5433750709
hasdemir52@gmail.com
Efe Hasdemir, MD
5433750709
emreerkal@hotmail.de
Artvin State Hospital
Interventions
  • Behavioral: Mandala Coloring — Mandala coloring activity performed for 30 minutes during outpatient chemotherapy using mandala coloring books and colored pencils.
Study Locations (1 sites)
Artvin State Hospital, Artvin, Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Being 18 years of age or older * Having a diagnosis of breast cancer and receiving chemotherapy * Having no communication problems * Having no physical disability that would prevent mandala coloring * Being willing to participate in the study Exclusion Criteria: * not meeting inclusion criteria
Conditions Cancer, Breast Cancer, Prostate Cancer, ...
Phase Not Applicable
Enrollment 45
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-06
Study Details Design, interventions, and primary outcomes

About This Study

This qualitative study seeks to explore the unmet needs of individuals who have recently undergone a cancer diagnosis and completed the acute phase of treatment. The primary objective is to utilize the experiences of patients, caregivers, and stakeholders to enhance the aftercare provided to cancer survivors. By delving into patient perceptions regarding unmet needs in cancer aftercare, the study aims to identify areas for redesigning and improving services to minimize these needs and ultimately enhance patient outcomes. Importantly, the investigation incorporates insights from patients, their caregivers, and stakeholders. The research will employ qualitative methods, specifically focus groups and interviews, to gather comprehensive perspectives from individuals in the Ausl IRCCS Reggio Emilia district who have completed treatment for breast, prostate, colorectal, thyroid, and multiple myeloma cancers. Including patients with diverse cancer types is crucial for capturing a broad spectrum of experiences. During data collection, both focus group discussions and interviews will be recorded in audio format and transcribed verbatim. This meticulous approach ensures an accurate representation of participants' voices and experiences. The subsequent analysis will employ a combination of framework and thematic analysis to extract meaningful insights and synthesize the data effectively. The study's ultimate goal is to leverage the findings to optimize aftercare services for cancer survivors within the local context of Ausl IRCCS Reggio Emilia. By incorporating the perspectives of patients, caregivers, and stakeholders, the research aims to contribute valuable insights that can inform the redesign and improvement of aftercare services, ultimately benefitting cancer survivors in the region.

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Interventions / Regimen

  • Other: Focus Groups or Interviews — Focus groups and qualitative interview will be conducted with patients, caregivers and stake-holders trying to identify unmet needs of cancer survivors after the acute treatment phase. Individual interviews (in presence or online) will be hold as alternative if it will not be possible (due to logistical or personal problems) to participate in a focus group or if the number of people who would have agreed to participate in that focus group is less than 3

Primary Outcomes

  • Experience of Self-reported perception of Unmet Needs (1- In the last three months 2- In the last 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-04-20
Completion: 2025-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Modena and Reggio Emilia
Collaborators: Azienda USL Reggio Emilia - IRCCS
Principal Investigators:
  • Stefania Costi, PhD (PRINCIPAL_INVESTIGATOR) - Physical Medicine and Rehabilitation Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia
Contact Information
Study Contact:
Angela Contri, MA
+393478824741
angela.contri@unimore.it
Stefania Costi, PhD
+390522522441
stefania.costi@unimore.it
Angela Contri, MA
+393478824741
angela.contri@unimore.it
Casa della Salute ex Spallanzani
Interventions
  • Other: Focus Groups or Interviews — Focus groups and qualitative interview will be conducted with patients, caregivers and stake-holders trying to identify unmet needs of cancer survivors after the acute treatment phase. Individual interviews (in presence or online) will be hold as alternative if it will not be possible (due to logistical or personal problems) to participate in a focus group or if the number of people who would have agreed to participate in that focus group is less than 3
Study Locations (1 sites)
Casa della Salute ex Spallanzani, Reggio Emilia, Reggio Emilia 42123 Italy
Eligibility Criteria
Inclusion Criteria: * Adult aged18 years or over. * Individuals who have a history of breast, prostate, thyroid, colorectal, multiple myeloma or lymphoma cancer within the past years who have completed the acute phase of treatment, and are in follow-up or are receiving maintenance treatment; * Caregivers for an individual who meets the above criteria, who are aged 18 years or over. * Stakeholders for individual who meets the above criteria, who are aged 18 years or over. Exclusion Criteria: * Individuals who do not wish to participate * Individuals who do not understand and/or speak Italian * Individuals with significant cognitive impairment, learning difficulty, or communication difficulty such that understanding the nature of the study, the interview questions, or participating in a focus group or an on-line or in-presence interview would not be practical.
Conditions Breast Cancer Female
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-06
Study Details Design, interventions, and primary outcomes

About This Study

Breast cancer is the most common cancer in the United States however, little is known about how diet can affect cancer treatment. Pre-clinical murine studies report intermittent fasting increases effectiveness of chemotherapy and decreases treatment related adverse events. The proposed research will demonstrate that time restricted eating, a form of intermittent fasting, will improve treatment related outcomes, patient related outcomes, and limit treatment related weight gain and fat mass accretion.Time restricted eating combined with a mediterranean diet will also be feasible and improve cardiometabolic risk more than TRE alone or standard care.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: TRE — All food eaten within the same self-selected 8 hour eating window daily, water fasting the remaining hours of the day.
  • Behavioral: MedTRE — A mediterranean style diet will be eaten within the same self-selected 8 hour eating window daily, water fasting the remaining hours of the day.

Primary Outcomes

  • Feasibility 8-h TRE (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-08-01
Completion: 2026-03-01
Eligibility
Age: 25 Years – 99 Years
Sex: FEMALE
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Illinois Chicago
Principal Investigators:
  • Kelsey Gabel, MS, RD, PhD (PRINCIPAL_INVESTIGATOR) - UIC
Contact Information
Study Contact:
Kelsey Gabel, PhD
312-413-8911
kdipma2@uic.edu
Kelsey Gabel, PhD
University of Illinois Chicago
Interventions
  • Behavioral: TRE — All food eaten within the same self-selected 8 hour eating window daily, water fasting the remaining hours of the day.
  • Behavioral: MedTRE — A mediterranean style diet will be eaten within the same self-selected 8 hour eating window daily, water fasting the remaining hours of the day.
Study Locations (1 sites)
University of Illinois Chicago, Chicago, Illinois 60612 United States
Eligibility Criteria
Inclusion Criteria: * Age 25-99 at time of consent * ECOG 0 or 1 * Breast cancer to meet histologically confirmed Stage I-III. * Demonstrates adequate organ function (absolutely neutrophil count ≥ 1,500/μL). * All screening labs to be obtained within 30 days prior to registration. * Able to provide written informed consent and HIPAA authorization for release of personal health information, via an approved UIC Institutional Review Board (IRB) informed consent form and HIPAA authorization. * Women of childbearing potential must not be pregnant or breast-feeding. A negative serum or urine pregnancy test is required per institutional practice guidelines. * As determined at the discretion of the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study. Exclusion Criteria: * Women with metastatic disease or type 1 or 2 diabetes * Women with BMI ≥ 40kg/m2 and \< 25kg/m2 * Women who are pregnant. A negative serum or urine pregnancy test is required per institutional practice guidelines. * Night shift workers * Women with a history of eating disorders * Enrolled participants with a significant weight loss or weight gain within 3 months of the study (weight gain or loss \>4kg) * Active infection requiring systemic therapy * Uncontrolled HIV/AIDS or active viral hepatitis * Pregnant or nursing * Any prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of this investigational regimen, as determined by the treating medical oncologist. * Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial. * Other major comorbidity, as determined by study PI * Illicit drug use or excessive use of alcohol (i.e., \> 2 drinks/day) * Currently participating in Weight Watcher's or another weight loss program * Myocardial infarction * Stroke * Congestive heart failure * Chronic hepatitis * Cirrhosis * Chronic pancreatitis * History of solid organ transplantation
Conditions Type 2 Diabetes, Gestational Diabetes, P...
Phase Not Applicable
Enrollment 350
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-06
Study Details Design, interventions, and primary outcomes

About This Study

In this prospective observational cohort study, women representing the full spectrum of gestational glucose tolerance status are undergoing longitudinal cardiometabolic characterization at regular intervals in the years after the index pregnancy.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: There is no intervention. An exposure of interest is glucose tolerance status in pregnancy

Primary Outcomes

  • Glucose tolerance status (10 years after pregnancy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2003-09
Completion: 2029-10
Eligibility
Age: 20 Years – 60 Years
Sex: FEMALE
Volunteers: true
Enrollment: 350 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mount Sinai Hospital, Canada
Collaborators: Canadian Institutes of Health Research (CIHR)
Principal Investigators:
  • Ravi Retnakaran, MD (PRINCIPAL_INVESTIGATOR) - MOUNT SINAI HOSPITAL
Contact Information
Study Contact:
Ravi Retnakaran, MD
416-586-4800
ravi.retnakaran@sinaihealth.ca
Ravi Retnakaran, MD
416-586-4800
ravi.retnakaran@SinaiHealth.ca
Mount Sinai Hospital
Interventions
  • Other: There is no intervention. An exposure of interest is glucose tolerance status in pregnancy
Study Locations (1 sites)
Mount Sinai Hospital, Toronto, Ontario M5G1X5 Canada
Eligibility Criteria
Inclusion Criteria: * Pregnant women Exclusion Criteria: * Pre-existing diabetes before the index pregnancy
Conditions Type 2 Diabetes, Non Alcholic Fatty Live...
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-06
Study Details Design, interventions, and primary outcomes

About This Study

Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver conditions ranging from liver steatosis (NAFL), steatohepatitis (NASH), advanced liver fibrosis and ultimately leads to cirrhosis in a significant proportion of individuals. NAFLD is intimately associated with insulin resistance and associated disorders, such as type 2 diabetes, metabolic syndrome and dyslipidemia. Bempedoic acid, an ATP-citrate lyase inhibitor, is recently approved for patients with dyslipidemia as a second line drug. Bempedoic acid reduces liver fat in mice model of NASH. Data regarding the effect of bempedoic acid on human liver fat are scarce. Therefore, the current study is planned to evaluate the effect of bempedoic acid versus standard treatment on liver and pancreatic fat content in patients with NAFLD

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Bempedoic acid — Patient willl be randomized 1:1 in both the arms

Primary Outcomes

  • The change in liver fat content (Baseline to 24 Weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-10-15
Completion: 2025-10-01
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medanta, The Medicity, India
Collaborators: Diabetes & Endocrinology Foundation
Contact Information
Study Contact:
Mr Surender, PhD
01244141414
yadavsurender89@gmail.com
Mohammad S kuchay, MBBS, MD
0124-4141414
drshafikuchay@gmail.con
Division Of Endocrinology , Medanta The Medicity Sec 38
Surender Rao, Msc
0124-4141414
yadavsurender89@gmail.com
Division Of Endocrinology , Medanta The Medicity Sec 38
Interventions
  • Drug: Bempedoic acid — Patient willl be randomized 1:1 in both the arms
Study Locations (1 sites)
Division Of Endocrinology , Medanta The Medicity Sec 38, Gurgaon, Haryana 122001 India
Eligibility Criteria
Inclusion Criteria: 1. A man or woman, 20 years of age or above with the diagnosis of type 2 diabetes for at least 3 months who meets all the following two criteria: 1. On standard anti-diabetic agents (metformin, DPP-4 inhibitors, sulphonylureas or insulin, in any combination) with an HbA1c of \<9% at screening 2. Have documented hepatic steatosis (MRI-PDFF \>5.6%) on screening MRI- PDFF 2. Participants must be medically stable based on medical history, physical examination and laboratory investigations. 3. Participants must be willing and able to adhere to the prohibitions and restrictions specified in this protocol. 4. Each participant must sign an informed consent form (ICF) indicating that he or she understands the purpose of the study and are willing to participate in the study. Exclusion Criteria: 1. History of diabetic ketoacidosis, type 1 diabetes, pancreas or beta-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy. 2. History of brittle or labile glycemic control, with widely varying glucose measurements by FPG or SMBG such that stable glucose control over the treatment period would be unlikely. 3. History of drug or alcohol abuse according to Diagnostic and Statistical Manual of Mental Disorders (5th edition) (DSM-V) criteria within 3 years before Screening, or an Alcohol Use Disorders Identification Test (AUDIT) with a score \>8, or alcohol consumption of more than 20 g per day in the case of women and more than 30 g per day in the case of men for at least three consecutive months during the previous 5 years. 4. Thyroid stimulating hormone (TSH) value that is either \< 0.45 mIU/L or \>10 mIU/L at Screening. Note: Subjects on thyroid hormone replacement therapy must be on a stable dose and dosing regimen for at least 4 weeks prior to enrollment. 5. Use of a PPAR-γ agonist \[e.g., a thiazolidinedione (pioglitazone\], an SGLT2 inhibitor (e.g., canagliflozin, empagliflozin, dapagliflozin), GLP-1 receptor agonists (e.g., liraglutide, dulaglutide) or saroglitazar (Dual PPARα/γ agonist) within 12 weeks before the enrollment. 6. BMI \>40 kg/m2. 7. Ongoing eating disorder, or a significant weight loss or weight gain within 12 weeks before the Screening visit, defined as an increase or decrease of 5% in body weight based upon clinic-based measurement or, if not available, based on subject's report. 8. Use of weight loss medication (prescription and/or over the counter) within 3 months prior to Screening or have participated in a weight loss/diet program within 12 months prior to Screening. 9. Renal disease that required treatment with immunosuppressive therapy or a history of dialysis or renal transplant. 10. Myocardial infarction, unstable angina, pulmonary hypertension, revascularization procedure (e.g., stent or bypass graft surgery), or cerebrovascular accident within 3 months before Screening, or revascularization procedure is planned, or subject has a history of New York Heart Association (NYHA) Class III-IV cardiac disease. 11. History of hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) positive, or other clinically active liver disease, or tests positive for HBsAg or anti- HCV at Screening. 12. Use of vitamin E within 12 weeks before screening. 13. History of prior bariatric (e.g., Roux-en-Y gastric bypass) or other major upper gastrointestinal surgical procedure (including gastric resection). 14. History of diabetic gastroparesis (or symptoms suggestive of this disorder, including postprandial bloating or vomiting), malabsorption, inflammatory bowel disease, or any other chronic, clinically important gastrointestinal disorder. 15. Estimated glomerular filtration rate (eGFR) \<60 mL/min/1•73 m2 using the Modification of Diet in Renal Disease Study (MDRD) equation. 16. Subjects with a history of having or possibly having metallic material in the body or any contraindication for a MR examination. 17. Claustrophobia, or anxiety related to previous negative experiences with magnetic resonance imaging procedures or if the subject is unwilling to participate in magnetic resonance imaging procedures. 18. Clinically important hematologic disorder (e.g., symptomatic anemia, proliferative bone marrow disorder, thrombocytopenia) at Screening. 19. History of human immunodeficiency virus (HIV) antibody positive at Screening. 20. Major surgery (e.g., requiring general anesthesia) within 12 weeks before Screening, or will not have fully recovered from surgery, or has surgery planned during the time the subject is expected to participate in the study. 21. Contraindications to the use of bempedoic acid (per BEMPEDOIC ACID Prescribing Information). 22. Current use of a corticosteroid medication or immunosuppressive agent, or likely to require treatment with a corticosteroid medication or an immunosuppressive agent.
Conditions Type 2 Diabetes
Phase PHASE3
Enrollment 800
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-06
Study Details Design, interventions, and primary outcomes

About This Study

This is a multicenter, randomized, double-blind, active-controlled, parallel-group study, which aims to provide data on the efficacy and safety of HDM1002 tablets compared with dapagliflozin in adults with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: HDM1002 100 mg — HDM1002 tablets, 100 mg once daily, 52 weeks
  • Drug: HDM1002 200 mg — HDM1002 tablets, 200 mg once daily, 52 weeks
  • Drug: HDM1002 400 mg — HDM1002 tablets, 400 mg once daily, 52 weeks
  • Drug: Dapagliflozin (DAPA) — dapagliflozin 10mg will be provided

Primary Outcomes

  • Change From Baseline in HbA1c at Week 40 (Baseline, Week 40)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-07-14
Completion: 2027-05-17
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Contact Information
Study Contact:
Dijun Zhou
+8613607307010
Z121300@126.com
Yueyang People's Hospital
Interventions
  • Drug: HDM1002 100 mg — HDM1002 tablets, 100 mg once daily, 52 weeks
  • Drug: HDM1002 200 mg — HDM1002 tablets, 200 mg once daily, 52 weeks
  • Drug: HDM1002 400 mg — HDM1002 tablets, 400 mg once daily, 52 weeks
  • Drug: Dapagliflozin (DAPA) — dapagliflozin 10mg will be provided
Study Locations (1 sites)
Yueyang People's Hospital, Yueyang, Hunan 414000 China
Eligibility Criteria
Inclusion Criteria: 1. Male or female subjects between 18 and 75 years of age (inclusive). 2. Have been diagnosed with type 2 diabetes mellitus (T2DM) for at least 3 months based on the World Health Organization, and participants treated with a stable dose of metformin (with maintenance dose of at least 1500 mg/day or a maximally tolerated dose not less than 1000 mg) for at least 8 weeks prior to screening; and must be stable for at least 12 weeks prior to randomization. 3. HbA1c ≥7.5% and ≤11.0% at screening as assessed by the local laboratory, and HbA1c ≥7.5% and ≤11.0% prior to randomization as assessed by the specified central laboratory. 4. Having a body mass index (BMI) of 19.0 to 40.0 kg/m2, inclusive. 5. Female participants of childbearing potential and male participants must agree to use highly effective contraception method from the day of signing the ICF and until 30 days (female) or 90 days (male) after the final dose administration. 6. Able to understand and comply with protocol requirements, agree to maintain the same dietary and exercise habits throughout the trial, be willing to complete the trial in strict compliance with the clinical trial protocol and provide written informed consent. Exclusion Criteria: 1. Diagnosed with type 1 diabetes mellitus (including latent autoimmune diabetes in adults), special types of diabetes or gestational diabetes mellitus 2. Evidence of acute complications of diabetes (e.g., diabetic ketoacidosis, diabetic lactosidosis, or hyperosmolar nonketotic coma) within 6 months prior to signing the informed consent form (ICF). 3. Have a known self or family history of medullary thyroid carcinoma, thyroid C-cell hyperplasia or multiple endocrine neoplasia type II (MEN2) 4. History of acute or chronic pancreatitis or pancreatic injury, or any high-risk factor which may lead to pancreatitis; or have symptomatic gallbladder disease that requires treatment during the trial (subjects with prior cholecystectomy can be enrolled if deemed eligible by the investigator) 5. Have had dysphagia, or any condition or disease possibly affecting gastric emptying or nutrients absorption in the opinion of the investigator, such as history of surgery affecting gastric emptying, gastroesophageal reflux disease, pyloric obstruction, irritable bowel syndrome, etc. 6. Have had any of the following within 3 months prior to screening: * Unstable angina; * Heart failure (New York Heart Association, class III or IV); * Myocardial infarction (MI); * Coronary artery bypass grafting or percutaneous coronary intervention; * Uncontrolled severe arrhythmias (including: ventricular tachycardia, ventricular fibrillation, atrial fibrillation, second to third degree atrioventricular block, sick sinus node syndrome, pre-excitation syndrome, etc.); * Cerebrovascular accident 7. Have a history of proliferative diabetic retinopathy and/or diabetic maculopathy that requires treatment, or evidence of other severe retinopathy that requires treatment during the study. 8. Have a known history of liver disease, including: acute or chronic active liver disease (except non-alcoholic steatohepatitis) such as active hepatitis B, hepatitis C; or primary biliary cholangitis. 9. Used strong CYP3A4 or P-gp inhibitors within 14 days prior to randomization or 5 half-lives (whichever is longer); current use with strong/moderate CYP3A4 inhibitors or strong P-gp inducers that cannot be discontinued during the trial; any prior use OATP1B1/OATP1B3 inhibitors; current use with narrow therapeutic index drugs that are substrates of CYP2C8, CYP3A4, UGT1A1, P-gp, or OATP1B1/OATP1B3 and cannot be discontinued during the trial. 10. Use of any glucose-lowering medication within 4 weeks prior to signing the ICF, including but not limited to: α-glucosidase inhibitors (e.g., acarbose), thiazolidinediones, and dipeptidyl peptidase-4 inhibitors (DPP-4i) inhibitors, glucose kinase activators, sodium-glucose cotransporter-2 inhibitors (SGLT-2i) ,with the exception of short-term insulin therapy due to a concomitant illness, stress, or perioperative period (cumulative duration ≤ 7 days). 11. Having used a Glucagon-like peptide-1 (GLP-1) analogue within 3 months prior to signing the ICF; or previous discontinuation of a GLP-1 analogue due to safety/tolerability or lack of efficacy. 12. Pregnancy or lactation. 13. Subjects with a known hypersensitivity to SGLT-2i or GLP-1 receptor agonists (GLP-1RA), or a history of severe drug allergies. 14. Enrolled in or participated in any other clinical study of drugs or medical devices within 3 months (or within 5 half-lives, whichever is longer) prior to signing the ICF (except for subjects who signed written informed consent without any intervention of investigational product or medical devices). 15. Any other condition considered by the investigator which is not suitable for participating in this study.
Conditions Heart Failure, Diabetes
Phase NA
Enrollment 800
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-06
Study Details Design, interventions, and primary outcomes

About This Study

A pragmatic electronic health record (EHR) based randomized controlled trial to evaluate the utility of providing Ultromics EchoGo analysis results and recommendations for HF risk prevention therapies using an EHR embedded clinical decision support tool.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Message with EchoGo — This alert will inform the provider that the patient has subclinical HFpEF
  • Behavioral: Standard Message — This alert will inform the provider of guideline directed treatment options for patients with diabetes to prevent heart failure.

Primary Outcomes

  • Frequency of prescription of SGLT-2i medication at outpatient clinic visits over 3 months follow-up (3-month follow-up)
  • Frequency of prescription of SGLT-2i medication at outpatient clinic visits over 6 months follow-up (3-month follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-06
Completion: 2027-07-15
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Texas Southwestern Medical Center
Principal Investigators:
  • Ambarish Pandey, MD (PRINCIPAL_INVESTIGATOR) - University of Texas Southwestern Medical Center
Contact Information
Study Contact:
Ambarish Pandey, MD
617-869-8957
Ambarish.Pandey@UTSouthwestern.edu
Ambarish Pandey, MD,MSCS
214-645-9762
UT Southwestern Medical Center
Interventions
  • Behavioral: Message with EchoGo — This alert will inform the provider that the patient has subclinical HFpEF
  • Behavioral: Standard Message — This alert will inform the provider of guideline directed treatment options for patients with diabetes to prevent heart failure.
Study Locations (1 sites)
UT Southwestern Medical Center, Dallas, Texas 75235 United States
Eligibility Criteria
Clinical cohort inclusion exclusion criteria: Inclusion Criteria: * Patients with diagnosis of Type 2 diabetes and High WATCH DM score. * Echocardiogram available in last 6-months. Exclusion Criteria: * History of HF * Not eligible for prescription of new GLP-1RA or SGLT2i or ns-MRA Corresponding providers to patients identified by the above inclusion exclusion criteria will be included in the clinical trial of the decision support tool.
Conditions Periodontitis, Adult, Prediabetes / Type...
Phase NA
Enrollment 600
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-06
Study Details Design, interventions, and primary outcomes

About This Study

This study will evaluate whether HbA1c screening can be performed in dental care to detect elevated blood glucose in patients with advanced periodontitis and support referral to primary care. Periodontitis is a common chronic inflammatory disease affecting the supporting tissues of the teeth. Advanced periodontitis is associated with prediabetes, type 2 diabetes and cardiovascular disease. The relationship between periodontitis and diabetes is bidirectional: diabetes increases the risk and severity of periodontitis, while periodontal inflammation may contribute to impaired glucose regulation. Patients with advanced periodontitis may therefore represent a group at increased risk of undetected elevated blood glucose. Many of these patients visit dental care regularly but may not otherwise be reached by structured medical prevention. This is a cross-sectional observational feasibility study conducted in public dental clinics in Skåne, Sweden, in collaboration with primary care. Adult patients aged 18 years or older with advanced periodontitis, defined as periodontitis stage 3-4 or grade B/C, will be invited to participate during a routine dental visit. Patients with previously diagnosed diabetes will not be included. After informed consent, participants will complete or update a health declaration and undergo capillary HbA1c testing at the dental clinic using a validated point-of-care instrument. Participants will receive their test result. Those with HbA1c ≥42 mmol/mol will receive standardized information and be referred to their listed primary care centre for further diagnostic assessment and preventive follow-up according to routine clinical practice. The study will assess how feasible this pathway is in routine dental care. Outcomes include participation rate, successful HbA1c testing, time required for study procedures, prevalence of elevated HbA1c, proportion referred to primary care, completed primary care follow-up within six months, dropout and costs. Follow-up data will be collected from medical records and regional registers. The study may provide a practical model for collaboration between dental care and primary care, with the long-term aim of improving early detection of prediabetes and diabetes and strengthening preventive care for patients with advanced periodontitis.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Point-of-care HbA1c screening — All participants undergo capillary HbA1c testing at the dental clinic using a validated point-of-care instrument. Test results are provided to the participant during the visit.
  • Other: Conditional standardized primary care referral — Participants with HbA1c ≥42 mmol/mol receive standardized information about the elevated test result and are referred to their listed primary care centre for further diagnostic assessment and preventive follow-up according to routine clinical practice.

Primary Outcomes

  • Participation rate (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-01
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Region Skane
Collaborators: Folktandvården Skåne AB
Contact Information
Study Contact:
Susanna Calling
+46724640728
susanna.calling@med.lu.se
Peter Nymberg
peter.nymberg@med.lu.se
Nils Oscarson
+46 70 277 33 57
nils.oscarson@folktandvardenskane.se
Folktandvården Skåne AB
Interventions
  • Diagnostic Test: Point-of-care HbA1c screening — All participants undergo capillary HbA1c testing at the dental clinic using a validated point-of-care instrument. Test results are provided to the participant during the visit.
  • Other: Conditional standardized primary care referral — Participants with HbA1c ≥42 mmol/mol receive standardized information about the elevated test result and are referred to their listed primary care centre for further diagnostic assessment and preventive follow-up according to routine clinical practice.
Study Locations (1 sites)
Folktandvården Skåne AB, Skåne, Sweden
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older. * Advanced periodontitis, defined as stage 3-4 periodontitis or grade B/C periodontitis according to clinical and radiographic assessment during routine dental care. * Ability to understand study information and provide informed consent. Exclusion Criteria: * Previously diagnosed diabetes mellitus. * Inability to provide informed consent, for example due to severe mental disorder or markedly impaired health status as judged by the clinical staff.
Conditions Lifestyle Factors, Overweight and Obesit...
Phase NA
Enrollment 70
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-06
Study Details Design, interventions, and primary outcomes

About This Study

The overall goal is to determine how a sleep extension intervention (increasing time in bed) in individuals who maintain less than 6.5 hours sleep per night affects their plasma ceramides and insulin sensitivity. Participants will undergo a randomized controlled trial, with sleep extension (intervention) and healthy lifestyle (control) groups. The sleep extension is designed to increase participant's time in bed by 2 hours per night. Alternatively, the control group will receive basic health information (e.g., physical activity, goal setting, and nutrition when eating out).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Sleep Extension Intervention — Sleep extension-based intervention focused on increasing time spent in bed by 2 hours per night by directly scheduling assigned bed and waketimes based on participant's individual schedules. Participants will receive weekly sleep tips and counseling on improving their sleep duration.

Primary Outcomes

  • Total Plasma Ceramides (Immediately after the intervention)
  • Insulin Sensitivity (Immediately after the intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-02-12
Completion: 2028-05
Eligibility
Age: 18 Years – 45 Years
Sex: ALL
Volunteers: true
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Utah
Contact Information
Study Contact:
Christopher M Depner, PhD
801-581-2275
christopher.depner@utah.edu
Christopher Depner
8015812275
sleepstudyparticipant@utah.edu
College of Health Research Complex--University of Utah
Interventions
  • Behavioral: Sleep Extension Intervention — Sleep extension-based intervention focused on increasing time spent in bed by 2 hours per night by directly scheduling assigned bed and waketimes based on participant's individual schedules. Participants will receive weekly sleep tips and counseling on improving their sleep duration.
Study Locations (1 sites)
College of Health Research Complex--University of Utah, Salt Lake City, Utah 84112 United States
Eligibility Criteria
Inclusion Criteria: 1. Age: 18-45 years old; equal numbers of men and women 2. Body mass index (BMI): 27.5-34.9 kg/m2 3. Sleep Habits: habitual self-reported average total sleep time (TST) \<6.5 hours per night for prior 6 months Exclusion Criteria: 1. Clinically diagnosed sleep disorder or major psychiatric illness 2. Evidence of significant organ dysfunction or disease (e.g., heart disease, kidney disease) 3. Clinically diagnosed diabetes or fasting plasma glucose ≥126 mg/dL or HbA1c ≥6.5% 4. Use of prescription drugs or substances known to influence sleep or glucose metabolism, or anticoagulant medications. 5. Cancer that has been in remission less than 5 years 6. Pregnant/nursing, experiencing menopause or post-menopausal 7. Shift-work: current or history of within last year 8. Weight change: \>10% of body weight over prior six months 9. Current enrollment in weight loss or physical activity program like the Diabetes Prevention Program 10. Currently smoking 11. Alcohol intake\>14 drinks per week or \>3 drinks per day
Conditions Diabete Type 2, Regurgitation, Pulmonary...
Phase Not Applicable
Enrollment 38
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-06
Study Details Design, interventions, and primary outcomes

About This Study

Treatment with semaglutide slows down gastric emptying , food remains in the stomach for a longer period of time. This slowing has important implications for anesthesia management. At present, we do not know the optimal duration for discontinuing this medication before surgery and anesthesia to ensure an empty stomach. This is an observational research project, conducted exclusively at the Geneva University Hospitals (HUG). To answer the research question, participation of 38 individuals will be required. The duration of participation for each person is 7 days. To recruit the necessary number of participants, approximately 1.5 years will be needed. This project is being carried out in accordance with Swiss legal requirements and recognized international guidelines. The competent ethics committee has reviewed and approved this project. The project will last 7 day during which the participants will need to come 3 times at the hospital to make gastric ultrasounds. On these days the participants will be asked to have a breakfast between 7 and 8 am including a minimum of bread and/or cereals and/or proteins. After that the participants will be asked to fast for 6 hours for solide food and 2 hours for liquids. If the participants smokes, they must for 12h before the exam. At 2Pm an anesthesiologist will welcome the participant to make the exam at the hospital to evaluate the gastric volume after what the participants will be able to get a small collation and go back home.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • A safe gastric volume for anesthesia in diabetic patients treated with GLP-1 analog after a 6 hours fasting period 7 day after the last injection. (1 week)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-04-01
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 38 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Geneva
Contact Information
Study Contact:
Rey-Millet Quentin RMQuentin Dr
+4179.55.380.54
quentin.rey-millet@hug.ch
Hôpitaux Universitaires de Genève
Rey-Millet RMQuentin Quentin, Dr
Hôpitaux Universitaires de Genève
Interventions
N/A
Study Locations (1 sites)
Hôpitaux Universitaires de Genève, Geneva, Canton of Geneva 1211 Switzerland
Eligibility Criteria
Inclusion Criteria: * Female/ Male of 18 years old or more * With Type 2 Diabetes * Treated with GLP 1 analog for more than 3 months * Signed consent * ASA between I and IV Exclusion Criteria: * Insuline treatment * Gastro intestinal motility disorders * Past gastric surgery * Hiatal hernia * Recent trauma * Inability to be lay down for the exam * Inability to follow the instructions for the exam (language, dementia) * BMI \> 40 * Inability to stop smoking 12h before the measures
Conditions Diabetes Mellitus, Psychological Distres...
Phase NA
Enrollment 290
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-06
Study Details Design, interventions, and primary outcomes

About This Study

Diabetes-related distress is a psychological construct associated with poorer glycaemic control in people living with diabetes. In France, few data are available on this topic and none focus specifically on adults with type 2 diabetes. Diabetes-related distress is not mentioned in the current French national guidelines on the management of type 2 diabetes, whereas international societies such as the ADA and, more recently, the EASD now recommend its regular assessment. This single-centre observational study conducted in the endocrinology department of Nice University Hospital aims to estimate the prevalence of severe diabetes-related distress in adults with type 2 diabetes receiving usual care, and to identify associated clinical, psychosocial and lifestyle factors. Participants complete validated self-report questionnaires (PAID-20 for diabetes distress, WHOQOL-BREF for quality of life, and a modified Starting The Conversation dietary questionnaire), and clinical data are extracted from electronic medical records. The study does not modify usual medical management and participation consists only in completing the questionnaires and receiving feedback on the results.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Behavioral: Questionnaire and Physical Exam — Patients will be asked to complete questionnaires.

Primary Outcomes

  • Prevalence of severe diabetes-related distress (PAID-20 score ≥ 40) (Baseline (single assessment during usual care visit, within 3 days from inclusion))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-15
Completion: 2027-01-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 290 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Hospitalier Universitaire de Nice
Principal Investigators:
  • Philippe CAROLI-BOSC, Dr (PRINCIPAL_INVESTIGATOR) - Centre Hospitalier Universitaire de Nice
Contact Information
Study Contact:
Philippe CAROLI-BOSC, Dr
+33 4 92 03 21 87
caroli-bosc.p@chu-nice.fr
CAROLI-BOSC Philippe, Dr
4 92 03 21 87
caroli-bosc.p@chu-nice.fr
CHU de Nice
Interventions
  • Behavioral: Questionnaire and Physical Exam — Patients will be asked to complete questionnaires.
Study Locations (1 sites)
CHU de Nice, Nice, France
Eligibility Criteria
Inclusion Criteria: * Adults (age ≥ 18 years). * Diagnosed with type 2 diabetes according to national (HAS) criteria, whether newly diagnosed or longstanding, with or without chronic complications, and with no restriction regarding HbA1c level. Patients with mixed diabetes (type 2 diabetes associated with pancreatic disease) may also be included if all of the following criteria are met: pancreatic disease detected on imaging, preserved C-peptide levels (\> 200 pmol/L in the presence of normal blood glucose levels), and BMI ≥ 25 kg/m². * Able to understand the study information and to complete the self-administered questionnaires. * Affiliated to the French social security system. * Has not objected to participation in the study (non-opposition procedure). Exclusion Criteria: * Age \< 18 years. * Pregnant woman. * Any type of diabetes other than type 2 diabetes (e.g. type 1 diabetes, secondary or genetic diabetes). * Haemochromatosis. * Cystic fibrosis. * Current treatment with one of the following hyperglycaemic therapies: oral corticosteroids, immunosuppressive drugs, dopaminergic agonists, interferon-alpha, or protease inhibitors. * History of partial or total pancreatectomy. * Ongoing genetic work-up for atypical diabetes. * Non-French-speaking patient. * Major neurocognitive disorder or physical/mental disability preventing completion of the questionnaires. * Adult under legal protection (guardianship or curatorship). * Refusal or subsequent withdrawal of non-opposition. * Any later paraclinical result finally revealing a type of diabetes other than type 2 diabetes.
Conditions Obesity and Overweight, Pre-diabetic, Ty...
Phase NA
Enrollment 240
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-06
Study Details Design, interventions, and primary outcomes

About This Study

Nutrition is very important to keep blood sugar levels balanced. If blood sugar levels are too high, it can lead to diseases such as cardiovascular disease and type 2 diabetes (T2DM). Therefore, adjusting what one eats, also called a diet or nutritional intervention, can help prevent these diseases. However, not everyone responds the same to a diet. In about 30% of people, a diet does not work as hoped. This can be due to various reasons, such as a person's metabolism, genetic predisposition, the composition of the food one eats, or the bacteria in the intestines. Everyday things like sleep, stress, and movement also play a role. The investigators used a computer model to classify people with overweight and obesity into groups based on these factors. The investigators call such a group a 'Metabolic Phenotype', or in short 'Metabotype'. Based on the Metabotype, a personalised diet was developed (personalised nutrition intervention) that may better suit each person's unique situation. The investigators hypothesize that a precision nutrition intervention, tailored to Metabotypes identified through unsupervised clustering (using the aforementioned computer model) of predefined, accurate features related to cardiometabolic health-specifically, tissue-specific glucose and lipid metabolism and detailed body composition-will enhance blood glucose homeostasis, reduce cardiometabolic risk, and improve adherence to the intervention and mental well-being, compared to population-based dietary guidelines. The present project will contribute to targeted and efficient precision-based dietary strategies for individuals at increased risk of T2DM.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Other: Optimal Metabotype-specific diet — Following screening, baseline measurements, and determination of Metabotype, participants will be randomly assigned, using minimisation, to either the Precision Nutrition (PN) group or the Control (CN) group. The PN group will receive a diet hypothesised to be optimal for their specific Metabotype. All participants will adhere to their assigned diets for 12 months. Each Metabotype-specific diet will align with the Dutch Healthy Dietary Guidelines, while varying in macronutrient composition and quality.
  • Other: Sub-optimal diet — Participants randomised to the Control Group (CN), will be randomly assigned one of the two diets optimised for a different Metabotype of the same sex. The assigned CN Group diet will always have a macronutrient content and quality that is different than their hypothesised optimal diet. All diets will align with the Dutch Healthy Dietary Guidelines.

Primary Outcomes

  • Matsuda Index (Change from baseline at month 6 and month 12 following dietary intervention.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-23
Completion: 2027-04
Eligibility
Age: 40 Years – 75 Years
Sex: ALL
Volunteers: true
Enrollment: 240 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Maastricht University Medical Center
Collaborators: Wageningen University and Research, Health Holland, TKI Agri & Food, Nestle Health Science, Beneo GmbH, BARILLA G. e R. Fratelli S.p.A., Parma, Italy
Principal Investigators:
  • Ellen E Blaak, Prof. Dr. Ir. (PRINCIPAL_INVESTIGATOR) - Maastricht University Medical Center
Contact Information
Study Contact:
Ellen E Blaak, Prof. Dr. Ir.
+31433881503
e.blaak@maastrichtuniversity.nl
Art Muijsenberg, MSc
+31433882862
art.muijsenberg@maastrichtuniversity.nl
Ellen E Blaak, Prof. Dr. Ir.
+31433881503
e.blaak@maastrichtuniversity.nl
Maastricht University Medical Center, Department of Human Biology, NUTRIM Institute of Nutrition and Translational Research in Metabolism
Interventions
  • Other: Optimal Metabotype-specific diet — Following screening, baseline measurements, and determination of Metabotype, participants will be randomly assigned, using minimisation, to either the Precision Nutrition (PN) group or the Control (CN) group. The PN group will receive a diet hypothesised to be optimal for their specific Metabotype. All participants will adhere to their assigned diets for 12 months. Each Metabotype-specific diet will align with the Dutch Healthy Dietary Guidelines, while varying in macronutrient composition and quality.
  • Other: Sub-optimal diet — Participants randomised to the Control Group (CN), will be randomly assigned one of the two diets optimised for a different Metabotype of the same sex. The assigned CN Group diet will always have a macronutrient content and quality that is different than their hypothesised optimal diet. All diets will align with the Dutch Healthy Dietary Guidelines.
Study Locations (2 sites)
Maastricht University Medical Center, Department of Human Biology, NUTRIM Institute of Nutrition and Translational Research in Metabolism, Maastricht, 6200MD Netherlands
Wageningen University and Research, Division of Human Nutrition, Wageningen, 6700AA Netherlands
Eligibility Criteria
Inclusion Criteria: * Men and women with a BMI ≥25 to \<40 kg/m2 * Classification possible to one of the investigational metabolic phenotypes according to the classification algorithm. * Weight stability for at least 3 months (+/- 3 kg) Exclusion Criteria: Diseases * (Pre-)diagnosis of type 1 or type 2 diabetes mellitus (i.e., FPG ≥ 7,0 mmol/L) and HbA1c ≥ 6,5% (48 mmol/mol) * Renal or hepatic malfunctioning (pre-diagnosis or determined based on ALAT and creatinine values) * Gastrointestinal diseases or abdominal surgery (allowed i.e.: appendectomy, cholecystectomy) * Food allergies, intolerances (including gluten/lactose intolerance) and/or eating disorders interfering with the study * Cardiovascular diseases (e.g., heart failure) or cancer (e.g., noninvasive skin cancer allowed) * High systolic blood pressure (untreated \>160/100 mmHg, drug-regulated \>140/90 mmHg) * Diseases affecting glucose and/or lipid metabolism (e.g., pheochromocytoma, Cushing's syndrome, acromegaly) * Diseases with a life expectation shorter than 5 years * Major mental disorders * Drug treated thyroid diseases (well substituted hypothyroidism is allowed inclusion) * Other physical/mental conditions that may interfere with study outcomes Medication * Medication known to interfere with study outcomes (e.g., PPAR-α or PPAR-γ agonists (fibrates), sulfonylureas, biguanides, α-glucosidaseinhibitors, thiazolidinediones, repaglinide, nateglinide, insulin, and chronic use of NSAIDs) * Use of certain anticoagulants other than acetylsalicylic acid * Use of antidepressants (stable use ≥ 3 months prior to and during study allowed) * Use of statins (stable use ≥ 3 months prior to and during study allowed) * Chronic corticosteroids treatment (\>7 consecutive days of treatment) * Use of antibiotics within 3 months prior to the study Lifestyle * Participation in regular sports activities (moderate-to-vigorous physical exercise \>4 hours per week) * Having a restricted dietary pattern interfering with the study diets (e.g., vegetarian, vegan, Atkins diet and/or other special diets) * Plans to lose or gain more than 5% body weight * Abuse of alcohol (alcohol consumption \>14 units/week) and/or drugs (cannabis included) * Not willing to limit alcohol consumption to 7 drinks per week * Regular smoking (including use of e-cigarettes and vapes) * Use of strong vitamins or other dietary supplements (e.g., pre- or probiotics) expected to interfere with the study outcomes Other * Metabotype classification is not possible * Pregnant or lactating women, or women who are planning to become pregnant * Inability to comply with the study diet * Blood donation within the last 3 months * Participation in possibly interfering studies within the last 3 months * Inability to understand study information and/or communicate with staff * Unwillingness to be randomised or sign informed consent * Unwillingness to save data for 15 years * Deemed unsuitable for participation in the trial, for any reason, as judged by the research physician or principal investigator